New diabetes drug accepted for review by FDA
PRINCETON, N.J. — The Food and Drug Administration has accepted a regulatory approval application for a Type 2 diabetes drug from Bristol-Myers Squibb and AstraZeneca, the two drug makers said Tuesday.
The FDA accepted the application for dapagliflozin, an investigational drug for adults with the disease. The Centers for Disease Control and Prevention estimated that 1-in-11 U.S. adults has diabetes, with 90% to 95% of them having Type 2 diabetes.
The agency expects to take action on the application in late October.
Walmart exec elected chair of health, benefits group
SAN FRANCISCO — Walmart’s U.S. VP benefits, Chris McSwain, was elected chairman of the Integrated Benefits Institute, the organization announced Monday.
“Chris McSwain has played an important leadership role in the health benefits community, and we look forward to his continued leadership with IBI,” said Thomas Parry, president of the nonprofit health and productivity research organization.
“The work done by IBI has played a critical role in helping employers and their supplier partners work more effectively to manage work force health and productivity,” McSwain said. “U.S. employers face both challenges and opportunities as we navigate health reform, and I’m excited to be working with IBI at this critical time.”
Others elected to leadership roles at the organization include Dan Lyon, VP and manager for Liberty Mutual, who was elected vice chair, and Anita Weir, manager of health services for Safeway, who was elected treasurer.
IBI provides employers and their supplier partners with resources for demonstrating the business value of health. As a pioneer, leader and nonprofit supplier of health and productivity research, measurement and benchmarking, IBI is a source for benefits performance analysis, research-based approaches and forums for information and education. IBI’s programs, resources and expert member networks advance understanding about the link between and the impact of health-related productivity on corporate America’s bottom line.
NACDS to host press conference in support of MTM bill
ALEXANDRIA, Va. — In line with NACDS RxImpact Day on Capitol Hill this week, the National Association of Chain Drug Stores will hold a press conference in support of S. 274, The Medication Therapy Management Empowerment Act of 2011.
The legislation, which was introduced by Sen. Kay Hagan, D-N.C., and cosponsored by Sens. Al Franken, D-Minn.; Sherrod Brown, D-Ohio; Tim Johnson, D-S.D.; and Ron Wyden, D-Ore., will be discussed Thursday at the Reserve Officers Association.
The conference will feature NACDS president and CEO Steve Anderson, who will discuss the importance of MTM, a professional service offered by pharmacists and other qualified health practitioners that helps ensure medications are taken appropriately, thus preventing higher costs and preventable forms of treatment.
The press conference is a component of the NACDS RxIMPACT Day on Capitol Hill, where more than 300 pharmacists, pharmacy students, executives and other pharmacy advocates will meet with lawmakers to advocate for pro-patient, pro-pharmacy policies.